ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia
2014
Abstract
Childhood acute lymphoblastic leukemia (ALL) demonstrates clinical and biological heterogeneity, which is largely sustained by a diverse genetic background. Today, the majority of children with ALL treated on modern treatment protocols can expect to achieve long-term cure, but still a significant proportion of patients suffer therapy-related toxicity and disease relapse.
Thus, identification of new prognostic markers to improve initial risk assessment for subsequent treatment tailoring remains an important goal in ALL research.